First-in-human (FIH) study of TAS-120, a highly selective covalent oral fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced solid tumors

被引：0

作者：

Kuboki, Y. ^{[1
]}

Matsubara, N. ^{[2
]}

Bando, H. ^{[3
]}

Shitara, K. ^{[3
]}

Yoh, K. ^{[4
]}

Kojima, T. ^{[3
]}

Ohno, I. ^{[5
]}

Takahashi, H. ^{[5
]}

Harano, K. ^{[1
]}

Kondo, S. ^{[6
]}

Hirai, H. ^{[7
]}

Morizane, C. ^{[6
]}

Doi, T. ^{[1
]}

机构：

[1] Natl Canc Ctr Hosp East, Dept Expt Therapeut, Kashiwa, Chiba, Japan

[2] Natl Canc Ctr Hosp East, Dept Breast & Med Oncol, Kashiwa, Chiba, Japan

[3] Natl Canc Ctr Hosp East, Dept Gastrointestinal Oncol, Kashiwa, Chiba, Japan

[4] Natl Canc Ctr Hosp East, Thorac Oncol, Kashiwa, Chiba, Japan

[5] Natl Canc Ctr Hosp East, Dept Hepatobiliary & Pancreat Oncol, Kashiwa, Chiba, Japan

[6] Natl Canc Ctr, Dept Hepatobiliary & Pancreat Oncol, Tokyo, Japan

[7] Taiho Pharmaceut Co Ltd, GCMO Off, Tokyo, Japan

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

372PD

引用

页数：1